 NEW YORK, June 1, 2021 PRNewswire -- Nuvation Bio Inc. NYSE: NUVB, a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D. 